| ALP | Alkaline phosphatase |
| ARPI | Androgen receptor pathway inhibitor |
| CI | Confidence interval |
| CR | Complete response |
| CRPC | Castration-resistant prostate cancer |
| CT | Computed tomography |
| CTCAE | Common Terminology Criteria for Adverse Events |
| DES | Diethylstilbestrol |
| DICOM | Digital Imaging and Communications in Medicine |
| DSMB | Data safety monitoring board |
| ECG | Electrocardiogram |
| ECOG | Eastern Cooperative Oncology Group |
| EMA | European Medicines Agency |
| FDA | Food and Drug Administration |
| GBq | Gigabecquerel |
| Gy | Gray |
| h | Hour |
| IEC | Independent ethics committee |
| ICRP | International Commission on Radiological Protection |
| IRB | Institutional Review Board |
| LDH | Lactate dehydrogenase |
| mCi | Millicurie |
| mCRPC | Metastatic castration-resistant prostate cancer |
| MBq | Megabecquerel |
| MedDRA | Medical Dictionary for Regulatory Activities |
| min | Minute/minimum |
| MIRD | Medical internal radiation dose |
| MRI | Magnetic resonance imaging |
| ORR | Objective response rate |
| OS | Overall survival |
| OSEM | Ordered-subset expectation maximization |
| PCWG3 | Prostate Cancer Working Group 3 |
| PET | Positron emission tomography |
| PR | Partial response |
| PSA | Prostate-specific antigen |
| PSMA | Prostate-specific membrane antigen |
| rADC | Radio antibody–drug conjugate |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| rPFS | Radiographic progression-free survival |
| RLT | Radioligand therapy |
| SD | Standard deviation |
| SOC | Standard of care |
| SPECT | Single-photon emission computed tomography |
| SSE | Symptomatic skeletal event |
| SUV | Standardized uptake value |
| SUVmax | Maximum standardized uptake value |
| Sv | Sievert |
| TEAE | Treatment-emergent adverse event |